Article Versions Notes

Marinelli D, Mazzotta M, Pizzuti L, Krasniqi E, Gamucci T, Natoli C, Grassadonia A, Tinari N, Tomao S, Sperduti I, et al. Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials. Cancers. 2020; 12(9):2497. https://doi.org/10.3390/cancers12092497

Marinelli, Daniele, Marco Mazzotta, Laura Pizzuti, Eriseld Krasniqi, Teresa Gamucci, Clara Natoli, Antonino Grassadonia, Nicola Tinari, Silverio Tomao, Isabella Sperduti, and et al. 2020. "Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials" Cancers 12, no. 9: 2497. https://doi.org/10.3390/cancers12092497

Marinelli, D., Mazzotta, M., Pizzuti, L., Krasniqi, E., Gamucci, T., Natoli, C., Grassadonia, A., Tinari, N., Tomao, S., Sperduti, I., Sanguineti, G., Botticelli, A., Fabbri, A., Botti, C., Ciliberto, G., Barba, M., & Vici, P. (2020). Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials. Cancers, 12(9), 2497. https://doi.org/10.3390/cancers12092497